MK-8719   Click here for help

GtoPdb Ligand ID: 10508

Synonyms: compound 42 [PMID: 31487175] | MK8719
PDB Ligand
Compound class: Synthetic organic
Comment: MK-8719 is an inhibitor of O-GlcNAcase (OGA) that is being investigated as a disease modifying strategy for neurodegenerative tauopathies (including Alzheimer's disease, Pick's disease and progressive supranuclear palsy) [3]. Development of MK-8719 is the result of a partnership between Merck and Alectos Therapeutics. MK-8719 was designed using on the scaffold of the carbohydrate-based lead molecule thiamet-G and used medicinal chemistry and SAR to improve on thiamet-G's less than favourable drug-like properties (e.g. potency, selectivity, CNS exposure and metabolic stability). The current status of OGA inhibitor development as a novel preventative mechanism in neurodegeneration and age-related memory impairment is reveiwed by Rudrawar and Ryan (2019) [2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 3
Rotatable bonds 3
Topological polar surface area 99.38
Molecular weight 268.07
XLogP 0.26
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCNC1=NC2C(S1)OC(C(C2O)O)C(F)F
Isomeric SMILES CCNC1=N[C@H]2[C@@H](S1)O[C@@H]([C@H]([C@@H]2O)O)C(F)F
InChI InChI=1S/C9H14F2N2O3S/c1-2-12-9-13-3-4(14)5(15)6(7(10)11)16-8(3)17-9/h3-8,14-15H,2H2,1H3,(H,12,13)/t3-,4-,5+,6+,8-/m1/s1
InChI Key UDQTXCHQKHIQMH-KYGLGHNPSA-N
No information available.
Summary of Clinical Use Click here for help
MK-8719 has been advanced to first-in-human phase 1 clinical trials. The FDA orphan drug designation granted to MK-8719 in early 2016, for the treament of progressive supranuclear palsy, was subsequently withdrawn according to FDA online records [1].